Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF 52 9-Day RSI is 22.70 as of Jul. 18, 2026. GuruFocus rates TSXV:WOLF with a GF Score™ of 52/100 and a GF Value™ of C$1.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,049 Drug Manufacturers companies, Grey Wolf Health ranks better than 96.38% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-18), Grey Wolf Health's 9-Day RSI is 22.70.
The industry rank for Grey Wolf Health's 9-Day RSI or its related term are showing as below:
TSXV:WOLF's 9-Day RSI is ranked better than 96.38% of 1049
companies
in the Drug Manufacturers industry
Industry Median: 53.26
vs TSXV:WOLF: 22.70
Grey Wolf Health (TSXV:WOLF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Grey Wolf Health 9-Day RSI Related Terms
TSXV:WOLF vs ROL, SCI, FTDR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's 9-Day RSI falls into.
Grey Wolf Health (TSXV:WOLF) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a 9-Day RSI of 22.70 as of Jul. 18, 2026. According to the industry distribution chart, Grey Wolf Health ranks #38 out of 1049 companies in the Drug Manufacturers industry, placing it in the top 3.6%.
Is Grey Wolf Health's 9-Day RSI too high?
Grey Wolf Health's current 9-Day RSI is 22.70. The Drug Manufacturers industry median 9-Day RSI is 53.26. Grey Wolf Health's value of 22.70 is 57.4% below this industry median. Based on the distribution chart, Grey Wolf Health ranks #38 out of 1049 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's 9-Day RSI compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #38 out of 1049 companies for 9-Day RSI. This places Grey Wolf Health in the top 4% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 53.26. Grey Wolf Health's value of 22.70 is 57.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 53.26, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current 9-Day RSI of 22.70 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 53.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current 9-Day RSI is 22.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.10, compared to a current price of C$1.60 — trading 45.5% above its estimated fair value. The current 9-Day RSI is 22.70 and 57.4% below the Drug Manufacturers industry median of 53.26. Grey Wolf Health's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current 9-Day RSI is 22.70 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.60 is trading 45.5% above its estimated GF Value™ of C$1.10.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
9-Day RSI: 22.70
GF Value™: C$1.10 vs. price of C$1.60 (45.5% above fair value)
Industry Position: 57.4% below the Drug Manufacturers median (#38 of 1049)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
